DBVT

Company Overview — What Does DBV Technologies S.A. Do?

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. DBV Technologies S.A. (DBVT) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Daniel Tassé and employs approximately 80 people. With a market capitalization of $1.2B, DBVT is one of the notable companies in the Healthcare sector.

DBV Technologies S.A. (DBVT) Stock Rating — Reduce (April 2026)

As of April 2026, DBV Technologies S.A. receives a Reduce rating with a composite score of 39.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.DBVT ranks #2,091 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, DBV Technologies S.A. ranks #234 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DBVT Stock Price and 52-Week Range

DBV Technologies S.A. (DBVT) currently trades at $21.01. The stock lost $0.39 (1.8%) in the most recent trading session. The 52-week high for DBVT is $26.18, which means the stock is currently trading -19.8% from its annual peak. The 52-week low is $3.91, putting the stock 437.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is DBVT Overvalued or Undervalued? — Valuation Analysis

DBV Technologies S.A. (DBVT) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 7.17x, versus the sector average of 2.75x. The price-to-sales ratio is 199.67x, compared to 1.66x for the average Healthcare stock.

At current multiples, DBV Technologies S.A. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

DBV Technologies S.A. Profitability — ROE, Margins, and Quality Score

DBV Technologies S.A. (DBVT) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -78.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -56.7% versus the sector average of -33.1%.

On a margin basis, DBV Technologies S.A. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -2601.5% (sector: -66.1%). Net profit margin stands at -2622.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 138.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DBVT Debt, Balance Sheet, and Financial Health

DBV Technologies S.A. has a debt-to-equity ratio of 38.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.67x, indicating strong short-term liquidity. Total debt on the balance sheet is $1M. Cash and equivalents stand at $70M.

DBVT has a beta of 0.19, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for DBV Technologies S.A. is 44/100, reflecting average volatility within the normal range for its sector.

DBV Technologies S.A. Revenue and Earnings History — Quarterly Trend

In TTM 2026, DBV Technologies S.A. reported revenue of $6M and earnings per share (EPS) of $-1.05. Net income for the quarter was $-133M. Gross margin was 100.0%. Operating income came in at $-132M.

In FY 2025, DBV Technologies S.A. reported revenue of $6M and earnings per share (EPS) of $-1.05. Net income for the quarter was $-147M. Revenue grew 35.8% year-over-year compared to FY 2024. Operating income came in at $-147M.

In Q3 2025, DBV Technologies S.A. reported revenue of $3M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-33M. Revenue grew 158.8% year-over-year compared to Q3 2024. Operating income came in at $-34M.

In Q2 2025, DBV Technologies S.A. reported revenue of $1M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-42M. Revenue grew 26.2% year-over-year compared to Q2 2024. Operating income came in at $-41M.

Over the past 8 quarters, DBV Technologies S.A. has demonstrated a growth trajectory, with revenue expanding from $1M to $6M. Investors analyzing DBVT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DBVT Dividend Yield and Income Analysis

DBV Technologies S.A. (DBVT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DBVT Momentum and Technical Analysis Profile

DBV Technologies S.A. (DBVT) has a momentum factor score of 72/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 68/100 reflects moderate short selling activity.

DBVT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, DBV Technologies S.A. (DBVT) ranks #234 out of 838 stocks based on the Blank Capital composite score. This places DBVT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DBVT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DBVT vs S&P 500 (SPY) comparison to assess how DBV Technologies S.A. stacks up against the broader market across all factor dimensions.

DBVT Next Earnings Date

No upcoming earnings date has been announced for DBV Technologies S.A. (DBVT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DBVT? — Investment Thesis Summary

The quantitative profile for DBV Technologies S.A. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Price momentum is positive at 72/100, suggesting the trend favors buyers.

In summary, DBV Technologies S.A. (DBVT) earns a Reduce rating with a composite score of 39.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DBVT stock.

Related Resources for DBVT Investors

Explore more research and tools: DBVT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DBVT head-to-head with peers: DBVT vs AZN, DBVT vs SLGL, DBVT vs VMD.